Gilead announced that the EMA's CHMP recommended marketing authorization for its Trodelvy and Keytruda combination therapy for metastatic triple-negative breast cancer. This positive opinion, based on strong Phase 3 data, positions the combination as a potential first-line treatment in the EU, significantly expanding Trodelvy's market opportunity.
Gilead's Trodelvy, in combination with Merck's Keytruda, received a positive opinion from the EMA's CHMP for first-line treatment of PD-L1 positive metastatic triple-negative breast cancer. This is a significant step towards market authorization in the EU, expected in late 2026, and represents a substantial expansion of Trodelvy's addressable market beyond its current monotherapy approval. For Gilead, this offers a long-term revenue growth opportunity for a key oncology asset. For Merck, it reinforces Keytruda's broad utility. Traders should see this as a positive catalyst for GILD, with potential for increased sales once full authorization is granted, and a continued strong outlook for MRK's oncology portfolio.